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	 A	simple,	rapid,	sensitive	and	eco‐friendly	liquid	chromatographic	method	was	developed	and
validated	 for	 the	 simultaneous	 determination	 of	 paracetamol	 (PAR),	 caffeine	 (CAF)	 and
codeine	(COD).	The	separation	was	performed	on	cyano	column	using	a	micellar	mobile	phase
consists	of	140	mM	sodium	dodecyl	sulfate,	25	mM	phosphate	buffer	and	10%	acetonitrile	at
pH	=	3.	The	analysis	was	performed	at	a	flow	rate	of	1	mL/min	and	a	column	temperature	of
30	 °C	 under	 direct	UV	 detection	 at	 210	 nm.	 Total	 analysis	 time	was	 below	 6	min.	 Baclofen
(BCF)	was	used	as	an	 internal	standard.	The	validation	was	performed	according	to	the	ICH
guidelines.	The	proposed	method	was	linear	over	the	ranges	of	0.2‐100.0,	0.02‐12.0	and	0.2‐
12.0	µg/mL	for	PAR,	CAF	and	COD,	respectively.	The	limits	of	detection	were	0.031,	0.007	and
0.054	µg/mL	and	limits	of	quantification	0.103,	0.02	and	0.164	µg/mL	for	PAR,	CAF	and	COD,
respectively.	The	results	show	that	the	procedure	is	suitable	for	the	routine	analysis	of	drugs
in	tablet	dosage	forms.	The	method	was	further	extended	to	the	determination	of	the	studied
drugs	in	spiked	human	plasma	with	mean	percentage	recoveries	of	99.61±0.530,	99.28±0.523
and	99.52±0.385	for	PAR,	CAF	and	COD,	respectively.	
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1.	Introduction	
	
Paracetamol	 is	 one	 of	 the	most	 popular	 over‐the‐counter	
analgesic	and	antipyretic	drugs	(Figure	1).	Paracetamol	 is	the	
analgesic	of	choice	for	mild	to	moderate	pain	and	for	reducing	
fever	 [1].	 Caffeine	 is	 a	 central	 nervous	 system	 stimulant,	
increasing	alertness	and	producing	agitation	(Figure	1).	It	also	
relaxes	smooth	muscle,	stimulates	cardiac	muscle,	and	appears	
to	 be	 useful	 in	 the	 treatment	 of	 some	 types	 of	 headache	 [2].	
Codeine	 is	 an	 opioid	 analgesic	 related	 to	morphine	 but	with	
less	 potent	 analgesic	 properties	 and	 mild	 sedative	 effects	
(Figure	 1).	 It	 also	 acts	 centrally	 to	 suppress	 cough	 [3].	
Paracetamol‐codeine‐caffeine	is	a	combination	product	that	is	
used	 to	 treat	 mild	 to	 moderate	 pain,	 such	 as	 headache,	
migraine,	 or	 even	 surgical	 pain	 [4].	 Paracetamol	 and	 codeine	
both	act	as	pain	killers	and	caffeine	as	a	stimulant.	
High	 Performance	 Liquid	 Chromatography	 (HPLC)	 has	
been	highly	used	in	the	quality	control	of	drugs	because	of	its	
sensitivity,	 reproducibility	 and	 specificity	 [5].	 HPLC	 has	
become	an	important	tool	for	the	analysis	of	single	and	various	
combinations	 of	 the	 studied	 drugs	 in	 pharmaceuticals	 or	 in	
biological	 fluids	 [6‐24].	 Nevertheless,	 only	 one	 method	 has	
been	 published	 for	 the	 simultaneous	 determination	 of	 the	
three	drugs	in	a	pharmaceutical	preparation	[10].	
	
 
	
Figure	1.	The	structural	formula	of	the	studied	drugs	paracetamol,	caffeine	
and	codeine	phosphate.	
	
Micellar	 liquid	 chromatography	 (MLC)	 is	 one	 of	 the	 very	
important	analytical	techniques.	Micellar	media	are	alternative	
eluents	 to	 conventional	 aqueous‐organic	 mixtures	 for	 the	
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separation	 of	 compounds	 of	 a	 wide	 range	 of	 polarities,	 in	
reversed‐phase	liquid	chromatography	(RPLC)	[25‐27].	
Micellar	 mobile	 phases	 usually	 need	 less	 quantity	 of	
organic	modifier	 and	 generate	 less	 amount	 of	 toxic	waste	 in	
comparison	 with	 aqueous‐organic	 solvents,	 so	 that	 they	 are	
less	 toxic,	 non‐flammable,	 biodegradable	 and	 relatively	
inexpensive	 [28‐30].	 Because	 of	 these	 advantages,	 MLC	 is	
considered	 an	 interesting	 technique	 for	 green	 chemistry	 that	
copes	with	current	concern	about	the	environment.	 It	proved	
to	be	a	useful	technique	in	the	determination	of	diverse	groups	
of	compounds	in	several	matrices	[31‐34].	
To	 the	 best	 of	 our	 knowledge,	 no	MLC	method	 has	 been	
reported	for	the	simultaneous	determination	of	PAR,	CAF	and	
COD.	The	present	study	describes	a	rapid,	simple,	selective	and	
green	 MLC	 method	 with	 UV	 detection	 for	 the	 simultaneous	
analysis	of	PAR,	CAF	and	COD	in	pharmaceutical	preparation,	
as	well	as	in	spiked	human	plasma	samples.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
LC	analyses	were	performed	on	a	Shimadzu	(Japan)	HPLC	
system	consisting	of	a	CMB‐20	Alite	system	controller,	a	pump	
(LC‐20	 AD),	 a	 column	 oven	 (CTO20AC)	 and	 UV/VIS	 detector	
(SPD‐20A).	This	equipment	has	a	degasser	system	(DGU	20	A).	
For	 data	 processing	 and	 acquisition,	 LC	 solution	 software	
version	1.3	 from	Shimadzu	was	used.	An	ultrasonicator	 from	
Merck	L‐7612	and	a	pH	Meter	from	Hanna	(USA)	were	used.	
	
2.2.	Materials	and	reagents	
	
All	 the	 chemicals	 used	 were	 of	 analytical	 reagent	 grade,	
and	the	solvents	were	of	HPLC	grade.	PAR,	CAF	and	COD	were	
kindly	provided	by	El‐Kahira	Pharm.	and	Chem.	Ind.	Co.,	Cairo,	
Egypt.	 Baclofen	 (BCF),	 used	 as	 internal	 standard	 (IS),	 was	
kindly	donated	by	Novartis	Pharma,	Cairo,	Egypt.	Fevadol	Plus	
tablets,	 manufactured	 by	 SPIMACO	 Al‐Pharmaceutical	 Plant,	
Al‐	 Qassime,	 Saudia	 Arabia.	 Triethylamine	 (TEA),	 sodium	
dihydrogen	 phosphate	 and	 orthophosphoric	 acid	 85%	 were	
obtained	 from	 Riedel‐deHäen	 (Sleeze,	 Germany).	 Sodium	
dodecyl	 sulphate	 (SDS),	 methanol,	 ethanol,	 n‐propanol,	
butanol,	 tetrahydrofuran	 and	 acetonitrile	 (HPLC	 grade)	were	
obtained	 from	 Sigma‐Aldrich	 (Germany).	 Human	 plasma	
samples	 was	 kindly	 provided	 by	 Mansoura	 University	
Hospitals,	Mansoura,	Egypt	and	were	kept	frozen	(‐20	°C)	until	
used	after	gentle	thawing.	
	
2.3.	Chromatographic	conditions	
	
Chromatographic	 separations	 were	 achieved	 on	 a	 Shim‐
pack	 Cyano	 column	 (150	mm	×	 4.6	mm	 i.d.)	 from	 Shimadzu.	
The	 mobile	 phase	 consists	 of	 25	 mM	 sodium	 dihydrogen	
phosphate	buffer	140	mM	SDS,	10%	acetonitrile.	The	pH	of	the	
mobile	phase	was	adjusted	to	pH	=	3.0	using	orthophosphoric	
acid	 and	 the	 flow	 rate	 were	 1	 mL/min.	 The	 column	 was	
operated	at	35	°C	and	the	wavelength	was	adjusted	at	210	nm.		
	
2.4.	Preparation	of	standard	solutions		
	
Stock	standard	solutions	of	PAR,	CAF,	COD	and	BCF	(IS)	(1	
mg/mL)	were	prepared	in	methanol	separately	with	the	aid	of	
ultrasonic	bath.	Working	standard	solutions	for	the	analytical	
application	 200	 µg/mL	 of	 CAF,	 200	 µg/mL	 of	 COD	 and	 500	
µg/mL	of	PAR	were	prepared	by	appropriate	dilution	with	the	
mobile	phase.	Standard	laboratory	prepared	mixture	solutions	
were	 prepared	 by	 mixing	 appropriate	 volumes	 of	 PAR,	 CAF	
and	 COD	 working	 standard	 solutions	 in	 10	 mL	 volumetric	
flasks	 and	 diluting	 to	 the	 volume	 with	 the	 mobile	 phase	
keeping	 the	 medicinally	 recommended	 ratios	 of	 50.0:3.0:0.8	
for	PAR,	CAF	and	COD,	respectively.	All	solutions	were	stored	
in	 the	 refrigerator	 and	were	 found	 to	be	 stable	 for	 at	 least	 5	
days	without	alteration.	
	
2.5.	Procedures	
	
2.5.1.	Preparation	of	calibration	graphs	
	
Accurately	measured	aliquot	volumes	of	the	suitable	drug	
working	 standard	 solutions	were	 transferred	 into	 a	 series	 of	
10	mL	volumetric	flasks,	so	that	the	final	concentration	was	in	
range	of	0.2‐100.0	µg/mL	for	PAR,	0.02‐12.00	µg/mL	for	CAF	
and	 0.2‐12.0	 µg/mL	 for	 COD.	 To	 each	 flask,	 5	 µg/mL	 (final	
concentration)	of	BCF	standard	solution	was	added	as	internal	
standard.	 Then,	 the	 solutions	were	 completed	 to	 the	 volume	
with	 the	 mobile	 phase.	 Aliquot	 of	 20	 µL	 were	 injected	
(triplicate)	 and	 eluted	 with	 the	 mobile	 phase	 under	 the	
optimum	chromatographic	conditions.	The	average	peak	area	
ratio	 (Drug/IS)	versus	 the	 final	concentration	of	 the	drugs	 in	
µg/mL	 was	 plotted.	 Alternatively,	 the	 corresponding	
regression	equations	were	derived.	
	
2.5.2.	Preparation	of	sample	solutions		
	
Ten	Fevadol®	Plus	tablets	were	weighed	then	crushed	to	a	
fine	 powder.	 An	 accurately	 weighed	 amount	 of	 the	 powder	
equivalent	 to	 500,	 30	 and	 8	 mg	 of	 PAR,	 CAF	 and	 COD,	
respectively	which	 (The	content	of	 one	 tablet)	 transferred	 to	
100	mL	 volumetric	 flask	 and	 80	mL	 of	methanol	was	 added.	
The	solutions	were	sonicated	for	30	min	and	vortex	mixed	for	
15	 min,	 and	 then	 diluted	 to	 the	 mark	 with	 methanol.	 The	
solutions	were	filtered	through	Whatman	filter	paper.	Aliquots	
containing	 suitable	 concentrations	 of	 the	 studied	 drugs	were	
analyzed	 as	 described	 under	 "Construction	 of	 calibration	
graphs".	 The	 nominal	 content	 was	 calculated	 either	 from	 a	
previously	 plotted	 calibration	 graph	 or	 using	 corresponding	
regression	equation.	
	
2.5.3.	Assay	of	PAR,	CAF	and	COD	in	human	plasma	samples	
	
The	spiked	plasma	sample	(500	µL)	was	diluted	to	10.0	mL	
with	 the	mobile	 phase	 to	 give	 a	 final	 concentration	 range	 of	
0.2‐2.0,	 0.02‐0.20	 and	 0.2‐0.8	 µg/mL	 for	 PAR,	 CAF	 and	 COD,	
respectively,	 with	 a	 constant	 concentration	 of	 BCF	 (0.5	
µg/mL),	 then	 vortex	 mixed.	 The	 solutions	 were	 filtered	
through	a	0.45	µm	cellulose	acetate	Syringe	 filter.	Aliquots	of	
20	µL	were	injected	(in	triplicate)	and	eluted	with	the	mobile	
phase	under	the	reported	chromatographic	conditions.	A	blank	
experiment	 was	 carried	 out	 simultaneously.	 The	 peak	 area	
ratios	 were	 plotted	 versus	 the	 concentration	 of	 the	 drug	 in	
µg/mL.	The	corresponding	regression	equations	were	derived.	
	
3.	Results	and	discussion	
	
A	micellar	mobile	phase	has	been	utilized	in	this	study	for	
determination	of	PAR,	CAF	and	COD	together.	Figure	2	shows	
that	the	three	drugs	were	well	separated	under	the	described	
chromatographic	conditions.		
	
 
	
Figure	 2.	 Typical	 chromatogram	 of	 standard	 PAR	 (100	 µg/mL),	 CAF	 (6	
µg/mL)	and	COD	(1.6	µg/mL)	using	BCF	(IS,	5	µg/mL).	
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3.1.	Method	development	and	optimization		
	
3.1.1.	Choice	of	column	
	
Trials	 were	 performed	 using	 three	 different	 columns	
including:	 Shimadzu	 VPODS	 C18	 column	 (150	 mm	 ×	 4.6	 mm	
i.d.),	 Shimadzu,	 Kyoto,	 Japan,	 CLC‐C8	 column	 (150	mm	 ×	 4.6	
mm	i.d.),	Shimadzu,	Kyoto,	Japan	and	Shim‐pack	cyano	column	
(150	 mm	 ×	 4.6	 mm	 i.d.).	 The	 C18	 column	 resulted	 in	 low	
resolution	between	PAR	and	solvent	peak	with	long	retention	
time	 for	COD	 (16.8	min).	On	 the	other	hand	using	C8	 column	
resulted	 in	 low	 resolution	 between	 PAR	 and	 CAF.	 The	 CN	
column	 was	 the	 most	 suitable	 one	 since	 it	 produced	
symmetrical	 peaks	 with	 high	 resolution	 and	 high	 sensitivity	
within	 a	 reasonable	 analysis	 time.	 As	 a	 consequence,	 CN	
column	 was	 used	 for	 further	 method	 development	 and	
optimization.	
	
3.1.2.	Mobile	phase	composition	
	
Several	 modifications	 in	 the	 mobile	 phase	 composition	
were	 performed	 in	 order	 to	 study	 the	 possibilities	 of	
improving	the	performance	of	chromatographic	system.	These	
modifications	 included	 the	 change	 of	 the	 type	 and	 %	
concentration	 of	 organic	 modifier,	 the	 concentration	 of	 SDS,	
concentration	of	buffer	and	pH	of	the	mobile	phase.		
	
3.1.3.	Type	of	the	organic	modifier	
	
Different	 organic	 modifiers	 were	 tried	 during	 the	
experimental	 study	 to	 choose	 the	 most	 suitable	 one	 for	
chromatographic	 separation	 of	 the	 three	 drugs.	 The	 studied	
organic	 modifiers	 included	 methanol,	 ethanol,	 n‐propanol,	
butanol,	 tetrahydrofuran,	 and	 acetonitrile.	 It	 was	 found	 that	
using	methanol	or	ethanol	 showed	delay	 in	 retention	 time	of	
COD.	 In	 addition,	 n‐propanol,	 butane	 land	 tetrahydrofuran	
gave	lower	sensitivity	and	slight	overlapping	between	PAR	and	
CAF.	So,	acetonitrile	was	the	organic	modifier	of	choice	giving	
good	 resolved	 and	 highly	 sharp	 peaks	 within	 a	 reasonable	
time.	
	
3.1.4.	Percentage	of	the	organic	modifier	
	
The	effect	of	changing	the	percentage	of	acetonitrile	on	the	
retention	 times	 and	 selectivity	 of	 the	 test	 solutes	 was	
investigated	 using	 mobile	 phases	 containing	 5‐20%	 of	
acetonitrile.	It	was	found	that	the	resolution	between	PAR	and	
CAF	is	decreased	upon	increasing	the	%	volume	of	acetonitrile.	
The	 study	 revealed	 that	 the	 optimum	 chromatographic	
performance	 was	 achieved	 upon	 using	 10%	 acetonitrile	
regarding	 the	 resolution	 and	 number	 of	 theoretical	 plates.	
Volumes	less	than	10%	resulted	in	 less	sensitive	peaks	and	it	
was	time	consuming.	
	
3.1.5.	Concentration	of	SDS	
	
The	 effect	 of	 changing	 the	 concentration	 of	 SDS	 on	 the	
selectivity	 and	 retention	 times	 of	 the	 test	 solutes	 was	
investigated	 using	mobile	 phases	 containing	 a	 concentration	
range	of	80‐160	mM	SDS.	It	was	found	that,	the	retention	time	
of	 COD	 increased	 upon	 decreasing	 the	 concentration	 of	 SDS.	
The	 study	 revealed	 that	 the	 optimum	 chromatographic	
performance	was	achieved	upon	using	140	mM	SDS	regarding	
the	 resolution	 of	 PAR	 and	 CAF	 and	 number	 of	 theoretical	
plates.	 Concentration	 more	 than	 140	 mM	 of	 SDS	 results	 in	
slight	decrease	in	the	number	of	theoretical	plates.		
	
3.1.6.	pH	of	the	mobile	phase	
	
The	 effect	 of	 changing	 the	 pH	 of	 mobile	 phase	 on	 the	
selectivity	 and	 retention	 times	 of	 the	 test	 solutes	 was	
investigated	using	mobile	phases	of	pH	ranging	from	3.0	to	7.0.	
It	 was	 found	 that,	 for	 COD	 the	 retention	 time	 was	 not	
dramatically	 changed.	 While,	 there	 is	 a	 gradual	 decrease	 in	
PAR	and	CAF	retention	with	the	increase	in	pH	from	4.0	to	6.0	
which	 is	not	 suitable	 for	 application	 in	plasma.	PAR	and	CAF	
peaks	were	not	completely	separated	at	pH	=	7.0.	It	was	found	
that	 pH	 =	 3.0	 was	 the	 most	 appropriate	 one	 yielding	 well	
resolved	peaks	and	highest	number	of	 theoretical	plates	with	
good	resolution	between	PAR	and	CAF.	
	
3.1.7.	Ionic	strength	of	the	buffer	
	
Besides	pH,	the	buffer	concentration	is	another	parameter	
controlling	 the	 resolution	 between	 PAR	 and	 CAF	 and	 the	
retention	 of	 COD.	The	method	was	 investigated	using	mobile	
phases	 containing	 concentrations	 of	 15‐45	mM	 of	 phosphate	
buffer.	It	was	found	that	the	resolution	between	PAR	and	CAF	
decreased	 and	 retention	 time	 of	 COD	 increased	 upon	
decreasing	 the	 ionic	 strength	of	 the	buffer.	As	a	 compromise,	
25	mM	phosphate	buffer	was	chosen	as	the	most	suitable	one	
giving	good	resolution	with	more	symmetrical	peaks.	
	
3.1.8.	Flow	rate	
	
The	 effect	 of	 flow	 rate	 on	 formation	 and	 separation	 of	
peaks	of	 studied	compounds	was	 investigated	over	 the	range	
0.8‐1.2	mL/min.	A	flow	rate	1	mL/min	was	optimal	for	highest	
theoretical	 plates	 count	 and	 good	 separation	 in	 reasonable	
time.	
	
3.1.9.	Column	temperature	
	
The	 effect	 of	 column	 temperature	 (from	 25	 to	 45	 °C)	 on	
formation	 and	 separation	 of	 peaks	 was	 studied.	 It	 can	 be	
concluded	 that	 highest	 theoretical	 plates	 count	 and	 good	
separation	 in	 a	 short	 retention	 time	 and	high	 sensitivity	was	
obtained	at	35	°C.	
	
3.1.10.	The	choice	of	the	internal	standard	
	
Different	 internal	 standards,	 such	 as	 meloxicam,	
diclofenac,	 celecoxibe	 and	 baclofen	were	 investigated.	 It	was	
found	that,	diclofenac	and	meloxicam	had	high	retention	time	
that	 increased	 the	retention	 time	of	 the	mixture	more	 than	6	
min	while	celecoxibe	peak	was	close	to	that	of	COD	peak	that	
led	 to	 overlapping	 between	 them.	 BCF	 was	 found	 to	 be	 the	
internal	 standard	 of	 choice	 as	 it	 produced	 good	 separation	
with	less	retention	time.	 	
	
3.1.11.	Method	validation	
	
Validation	 of	 the	 proposed	 method	 was	 performed	 with	
respect	to	linearity,	and	range,	LOD,	LOQ,	accuracy,	precision,	
specificity,	 stability	 and	 robustness	 according	 to	 the	
international	 conference	 on	 harmonization	 (ICH)	 Guidelines	
[35].		
		
3.1.12.	Linearity	and	range	
	
Under	 the	 above	 described	 experimental	 conditions,	 a	
linear	relationship	was	constructed	by	plotting	 the	peak	area	
ratios	 of	 PAR,	 CAF	 and	 COD	 to	 the	 internal	 standard.	 The	
concentration	 ranges	 were	 found	 to	 be	 0.2‐100.0	 µg/mL	 for	
PAR,	0.02‐12.00	µg/mL	 for	CAF	and	0.2‐12.0	µg/mL	 for	COD.	
Linear	 regression	 analysis	 of	 the	 data	 gave	 the	 following	
equations:		
	
y	=	0.299x	+	0.0045	(r	=	0.9999)	for	PAR	 	 (1)	
	
y	=	0.450x	‐	0.0014	(r	=	0.9999)	for	CAF	 	 (2)	
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Table	1.	Analytical	performance	data	for	the	determination	of	the	PAR,	CAF	and	COD	by	the	proposed	method.	
Parameters	 PAR		 CAF	 COD	
Linearity	range	(µg/mL)	 0.2‐100.0 0.02‐12.00 0.2‐12.0	
Correlation	coefficient	(r)	 0.9999 0.9999 0.9999	
Intercept	(a)	 0.0045 ‐0.0014 0.0212	
Slope	(b)	 0.2999 0.4500 0.5475	
SD	of	residuals	(Sy/x)	 0.0066	 0.00413	 0.0176	
SD	of	intercept	(Sa)	 0.0031	 0.0019	 0.0092	
SD	of	slope	(Sb)	 0.0006 0.0003 0.0016	
%	RSD	(SD	×	100/X`)	 0.560	 0.617	 0.803	
%	Error	(%	RSD/√n)	 0.197	 0.251	 0.303	
Limit	of	detection,	LOD	(μg/mL)	 0.031 0.007 0.054	
Limit	of	quantitation,	LOQ	(μg/mL) 0.103 0.020 0.164	
	
	
Table	2.	Assay	results	for	the	determination	of	PAR,	CAF	and	COD	in	raw	materials.	
Compound	 Proposed	method	 Comparison	method	[10]
Amount	taken	(µg/mL)	 Amount	found	(µg/mL) %	Found
PAR	 0.200	 0.199	 99.50	 99.95	
1.000	 0.998	 99.88	 99.54	
5.00	 4.94 98.80 100.98	
15.00	 15.09	 100.60	 	
50.00	 49.89 99.78 	
100.00	 99.65 99.65 	
x‐±SD	 99.85±0.53	 100.15±0.741	
Student	t‐test	 1.43(2.31)	 	
F‐test	 1.83(5.14) 	
CAF	 0.0200	 0.0199 99.95 99.95	
0.200	 0.199	 99.50	 99.71	
0.500	 0.498 99.60 100.30	
3.00	 3.01 100.30 	
12.00	 11.91	 99.20	 	
x‐±SD	 99.61±0.582 99.98±0.296	
Student	t‐test	 1.38	(2.31)	 	
F‐test	 1.57	(5.14) 	
COD	 0.200	 0.198 99.40 99.54	
0.400	 0.398 99.50 100.10	
1.200	 1.198	 99.80	 99.97	
4.00	 4.98 99.60 	
12.00	 11.87	 98.90	 	
x‐±SD	 99.51±0.571 99.87±0.293	
Student	t‐test	 1.461	(2.31) 	
F‐test	 1.982	(5.14)	 	
The	figures	between	parentheses	are	the	tabulated	t	and	F	values	at	p	=	0.05	[35].	
	
	
y	=	0.547x	+	0.0210	(r	=	0.9998)	for	COD	 	 (3)	
	
where	 y	 is	 the	 peak	 area	 ratio,	 x	 is	 the	 concentration	 of	 the	
drug	in	μg/mL	and	r	is	the	correlation	coefficient.		
Statistical	 analysis	 of	 the	 data	 gave	 high	 values	 of	 the	
correlation	 coefficients	 with	 small	 intercepts	 indicating	 the	
good	 linearity	of	calibration	graphs.	Statistical	 analysis	of	 the	
data	 gave	 high	 values	 of	 the	 correlation	 coefficient	 (r)	 of	
regression	equations	 [35].	Small	values	of	standard	deviation	
of	 residuals	 (Sy/x),	 of	 intercept	 (Sa),	 and	of	 slope	 (Sb)	 indicate	
low	 scattering	 of	 the	 points	 around	 the	 calibration	 curves.	
Also,	 small	 values	 of	 percentage	 relative	 standard	 deviation	
(RSD	%)	 and	 the	 percentage	 relative	 errors	 (%	 Er)	 indicate	
high	 accuracy	 and	 high	 precision	 of	 the	 proposed	 method	
(Table	1).	
	
3.1.13.	Limit	of	quantification	and	limit	of	detection	
	
The	 limits	 of	 quantification	 (LOQ)	 were	 determined	 by	
establishing	the	lowest	concentrations	that	could	be	measured	
according	to	ICH	Q2	(R1)	recommendations	[36]	below	which	
the	calibration	graphs	were	nonlinear.	The	 limits	of	detection	
(LOD)	were	determined	by	establishing	the	minimum	levels	at	
which	the	analytes	could	be	reliably	detected.	
	
LOQ	=	10	Sa/b	and	LOD	=	3.3	Sa/b	 	 (4)	
	
where	 Sa	 =	 Standard	 deviation	 of	 the	 intercept	 of	 the	 calib‐
ration	curve	and	b	=	Slope	of	the	calibration	curve.	
LOQ	 values	 were	 found	 to	 be	 0.103,	 0.020	 and	 0.164	
µg/mL	while	 LOD	 values	were	 found	 to	 be	 0.031,	 0.007	 and	
0.054	µg/mL	for	PAR,	CAF	and	COD,	respectively	as	shown	in	
(Table	1).	
	
3.1.14.	Accuracy	and	precision	
	
To	prove	the	accuracy	and	utility	of	the	proposed	method,	
the	results	of	the	assay	of	studied	drugs	were	compared	with	
those	 obtained	 using	 comparison	 method	 [10].	 Statistical	
analysis	 of	 the	 results	 obtained	 using	 Student’s	 t‐test	 and	
variance	 ratio	 F‐test	 [35]	 revealed	 no	 significant	 difference	
between	 the	 performance	 of	 the	 two	methods	 regarding	 the	
accuracy	and	precision,	respectively	(Table	2).		
Intra‐day	 precision	 was	 assessed	 by	 analyzing	 three	
concentrations	 and	 three	 replicates	 of	 each	 concentration	 in	
one	day.	Also,	 the	 inter‐day	precision	was	assessed	by	analy‐
zing	three	concentrations	and	three	replicates	of	each	concent‐
ration	 over	 three	 successive	 days.	 The	 relative	 standard	
deviations	were	 found	 to	be	very	small	 indicating	reasonable	
repeatability	 and	 intermediate	 precision	 of	 the	 proposed	
method	(Table	3).		
	
3.1.15.	Specificity	
	
Specificity	was	checked	by	analyzing	PAR,	CAF	and	COD	in	
laboratory	prepared	mixtures.	Good	resolution	and	absence	of	
interference	 between	 drugs	 being	 analyzed	 and	 other	
materials	in	the	pharmaceutical	formulations	(Figure	3)		
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Table	3.	Precision	data	for	the	determination	of	PAR,	CAF	and	COD	by	the	proposed	method.	
Parameter	 PAR	concentration	(µg/mL) CAF	concentration	(µg/mL)	 COD	concentration	(µg/mL)	
10	 20	 30 2.5 5 10 3 6	 9
Intraday	a	 %Found	 98.54	 99.32 98.92 100.12 99.99 99.29 100.03	 99.67	 100.11
99.51	 98.76	 99.58	 99.97	 100.58	 100.09	 98.92	 99.23	 100.05	
100.32	 99.87	 100.09 98.54 99.71 99.61 99.98	 98.89	 99.97
Mean 99.45	 99.31	 99.53	 99.54	 100.09	 99.66	 99.64	 99.26	 100.04	
±	SD	 0.891	 0.555	 0.586 0.782 0.444 0.402 0.626	 0.391	 0.070
%RSD	 0.892	 0.558	 0.588 0.785 0.443 0.403 0.628	 0.393	 0.069
%Error	 0.516	 0.322	 0.339 0.453 0.256 0.232 0.362	 0.227	 0.040
Interday	b	 %Found	 99.89	 99.93	 100.16 99.21 99.54 98.97 99.97	 98.93	 99.76
99.74	 99.65	 99.87	 100.01	 100.09	 99.91	 99.85	 99.62	 100.05	
100.09	 99.12	 99.81 99.96 99.88 99.57 100.09	 100.03	 99.87
Mean	 99.90	 99.56	 99.94	 99.72	 99.83	 99.48	 99.97	 99.52	 99.89	
±	SD	 0.175	 0.411	 0.187 0.448 0.277 0.476 0.120	 0.555	 0.146
%RSD	 0.175	 0.412	 0.187 0.449 0.277 0.478 0.120	 0.557	 0.146
%Error	 0.101	 0.238	 0.107	 0.259	 0.160	 0.275	 0.069	 0.321	 0.084	
a	Within	the	day.	 	
b	Three	consecutive	days.	
	
Table	4.	Robustness	evaluation	of	the	proposed	method.	
Variation Resolution	 Tailing	factor %	Recovery 
CAF/COD	 PAR/CAF	 PAR	 CAF	 COD	 PAR	 CAF	 COD	
23	mM	buffer 8.4	 2.4	 1.08 1.09 1.03 99.61	 99.80	 100.15
27	mM	buffer	 8.2	 2.3 1.03 1.04 0.99 99.00	 99.11	 99.88
0.145	M	SDS	 8.2	 2.3	 1.07 1.08 1.03 99.59	 99.75	 100.18
0.135	M	SDS	 8.1	 2.2	 1.02 1.03 0.99 99.08	 99.18	 99.83
11%	Acetonitrile	 8.8	 2.9	 1.03	 1.05	 1.01	 99.41	 99.76	 99.98	
9%	Acetonitrile	 8.1	 2.2	 0.97	 1.00	 0.95	 99.84	 99.84	 100.20	
pH	=	2.8	 8.8	 2.6	 1.01	 1.03	 0.98	 99.31	 99.53	 100.14	
pH	=	3.2	 8.6	 2.7	 0.99 1.00 0.96 99.51	 99.72	 100.11
Flow	rate	0.8	mL	 8.8	 2.9	 1.00	 1.02	 0.97	 99.23	 99.44	 99.87	
Flow	rate	1.2	mL	 8.5	 3.1	 1.01 1.03 0.99 99.32	 99.51	 99.98
Temperature	30	°C	 8.4	 2.4	 1.01 1.03 0.98 99.18	 99.28	 99.64
Temperature	40	°C	 8.9	 3.0	 0.99 1.01 0.96 99.50	 99.70	 100.11
Without	variation	 8.7	 2.8	 1.00 1.02 0.97 99.45	 99.66	 100.06
	
	
 
	
Figure	3.	HPLC	chromatogram	of	 tablets	 (50	µg/mL)	PAR,	 (3	µg/mL)	CAF	
and	(0.8	µg/mL)	COD	using	BCF	(IS,	5	µg/mL).	
	
confirming	the	specificity	of	the	method.	Good	recoveries	were	
obtained	 in	 the	 sample	 indicating	 specificity	 of	 the	 proposed	
method.	 Additionally,	 there	 was	 not	 any	 interference	
encountered	 from	 human	 plasma	 matrix	 although	 no	 prior	
extraction	procedure	was	performed.		
	
3.1.16.	Stability	
	
Stability	 of	 the	 standard	 solutions	 of	 the	 studied	 drugs,	
stored	at	4	°C,	was	evaluated	at	various	time	points	over	two	
weeks.	 The	 concentrations	 of	 freshly	 prepared	 solutions	 and	
those	 aged	 for	 two	 weeks	 were	 calculated	 by	 the	 method	
developed	and	the	difference	between	them	was	found	to	be	<	
0.4%.	 These	 solutions	 can	 therefore	 be	 used	 during	 this	
interval	of	time	without	the	results	being	affected.	
	
3.1.17.	Robustness	of	the	method	
	
Robustness	of	the	method	was	investigated	by	varying	the	
chromatographic	conditions	such	as	the	flow	rate,	the	amount	
of	acetonitrile	in	the	mobile	phase,	the	pH	of	the	mobile	phase,	
the	temperature	and	the	amount	of	SDS	in	the	mobile	phase.		
In	 this	 study,	 the	 chromatographic	 responses	 monitored	
were	 resolution,	 tailing	 factor	 and	 the	 percent	 recoveries	 of	
the	 studied	 drugs.	 (Table	 4)	 shows	 the	 experimental	 para‐
meters	performed	 for	 robustness	 evaluation.	Therefore,	 little	
variations	in	the	chromatographic	conditions	were	found	to	be	
acceptable	 values	 in	 relation	 to	 the	 reference	 value	 and	 the	
developed	method	for	analysis	was	considered	to	be	robust.		
	
3.2.	Applications	
	
3.2.1.	Dosage	form	analysis	
	
The	 proposed	 method	 was	 successfully	 applied	 to	 the	
simultaneous	determination	of	PAR,	CAF	and	COD	in	their	co‐
formulated	tablets	as	illustrated	in	Figure	3.	The	results	of	the	
proposed	 method	 were	 favorably	 compared	 with	 those	
obtained	 using	 the	 comparison	method	 [10].	 The	 results	 are	
abridged	in	Table	5.	Statistical	analysis	of	the	results	obtained	
using	 Student’s	 t‐test	 and	 variance	 ratio	 F‐test	 [35]	 revealed	
no	significant	difference	between	 the	performance	of	 the	 two	
methods	 regarding	 the	 accuracy	 and	 precision,	 respectively	
(Table	5).	
	
3.2.2.	Biological	applications	
	
Following	 oral	 administration	 of	 a	 single	 500	 mg	
conventional	 tablet	or	 a	 single	650	mg	extended‐release	PAR	
tablet,	 the	average	plasma	concentrations	was	reported	 to	be	
2.1	or	1.8	µg/mL	after	6	or	8	hours,	respectively	[37].	For	CAF	
after	 oral	 administration	 of	 100	 mg,	 peak	 plasma	
concentrations	of	about	1.5‐1.8	µg/mL	are	reached	after	50‐75	
minutes	 [38].	 While	 for	 COD,	 60	 mg	 orally,	 produces	 peak	
blood	 levels	 of	 150	 ng/mL	 in	 30	 minutes	 [39].	 The	 plasma	
calibration	curve	was	linear	with	the	following	equation,	linear	
regression	analysis	of	the	data	gave	the	following	equation:	
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Table	5.	Assay	results	for	the	determination	of	the	PAR,	CAF	and	COD	in	their	co‐formulated	tablet	by	the	proposed	and	comparison	methods.	
Preparation	 Amount	taken		
(µg/mL)	
Amount	found	
(µg/mL)	
%	Found	 Comparison	method	[10]	
PAR	 CAF	 COD	 PAR	 CAF	 COD	 PAR	 CAF	 COD	 PAR	 CAF	 COD	
Fevadol	Plus	®	tablets	
[500	mg	PAR	+	30	mg	CAF	+	8	mg	
COD]	
100	 6.0	 1.6 100.13 6.010 1.589 100.13 100.16 99.35	 100.01	 99.94 98.89
50	 3.0	 0.8 50.22 2.990 0.791 100.44 99.66 98.90	 100.27	 99.31 99.76
25	 1.5	 0.4 25.02 1.502 0.398 100.08 100.13 99.74	 99.93	 100.15 99.81
Mean	 	 	 	 	 	 	 100.21	 99.98	 99.33	 100.07	 99.80	 99.48	
±SD	 	 	 	 0.195 0.280 0.420	 0.177	 0.437 0.517
%	RSD	 	 	 	 0.194 0.280 0.422	 0.176	 0.437 0.522
%	Error	 	 	 	 0.112 0.161 0.244	 0.102	 0.252 0.301
Student	t‐test	 	 	 	 0.962	 0.658 0.407	 	 	
F‐test	 	 	 	 1.204 1.748 1.515	 	 	
The	values	of	tabulated	t‐	and	F‐tests	are	2.31	and	5.14	respectively	at	p	=	0.05	[35].	
	 	
Table	6.	Assay	Results	for	the	determination	of	the	studied	drugs	in	spiked	human	plasma	using	the	proposed	method.	
Parameter	 Amount	added	(µg/mL)	 Amount	found	(µg/mL)	 %	Found	
PAR	 CAF	 COD	 PAR CAF COD PAR CAF	 COD
Data	 0.2	 0.02	 0.2	 0.198 0.0198 0.1991 99.01 99.45	 99.55
1.0	 0.1	 0.6	 0.999 0.0997 0.5994 99.99 99.70	 99.90
2.0	 0.2	 0.8	 1.997 0.1974 0.7930 99.85 98.70	 99.13
Mean	 		 99.61	 99.28	 99.52	
±SD	 	 0.530 0.523	 0.385
%	RSD	 	 0.532 0.523	 0.386
%	Error	 	 0.307 0.302	 0.223
	
	
	
	
Figure	4.	HPLC	chromatogram	of	(A):	PAR	(2	µg/mL),	CAF	(0.2	µg/mL)	and	COD	(0.2	µg/mL)	using	BCF	(IS,	0.5	µg/mL)	in	spiked	human	plasma,	(B):	blank	
human	plasma.	
	
	
y	=	0.1648x	+	0.0730	(r	=	0.9998)	for	PAR	 	 (5)	
	
y	=	0.5860x	+	0.0803	(r	=	0.9999)	for	CAF	 	 (6)	
	
y	=	0.3575x	+	0.0365	(r	=	0.9999)	for	COD	 	 (7)
	 	
where	y	 is	the	peak	area,	x	 is	the	concentration	of	the	drug	in	
µg/mL	 and	 r	 is	 the	 correlation	 coefficient.	 The	 results	 of	 the	
analysis	of	PAR,	COD	and	CAF	in	plasma	samples	are	provided	
in	 (Table	 6).	 The	 accuracy	 of	 the	 proposed	 method	 was	
assessed	 by	 investigating	 the	 recovery	 of	 them	 at	 three	
concentration	 levels	 covering	 the	 specified	 range.	 The	
tabulated	 recoveries	 indicate	 good	 accuracy.	 Figure	 4	
represents	 a	 typical	 chromatogram	 of	 three	 drugs	 and	 the	
internal	standard	in	blank	and	spiked	human	plasma	samples.	
	
4.	Conclusion	
	
A	novel	and	rapid	micellar	less	hazardous	and	toxic	liquid	
chromatographic	method	was	examined	for	 the	simultaneous	
determination	 of	 PAR,	 CAF	 and	 COD.	 The	 developed	method	
has	 distinct	 advantages	 regarding	 analysis	 time	 and	 cost	
compared	with	those	of	the	previously	reported	methods.	The	
method	is	linear	over	a	wide	range	and	utilizes	a	mobile	phase	
which	 can	 be	 easily	 prepared.	 The	 proposed	 procedure,	 by	
virtue	of	its	high	sensitivity,	could	be	applied	to	the	analysis	of	
PAR,	CAF	and	COD	in	spiked	human	plasma	with	no	need	for	
extraction	or	pretreatment	steps.	
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